Italiano, Antoine <br/><br/>
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.  [electronic resource] 

 -  The Lancet. Oncology  05 2018 
 - 649-659 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(18)30145-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Benzamides--administration & dosage<br/>Biphenyl Compounds<br/>Dose-Response Relationship, Drug<br/>Enhancer of Zeste Homolog 2 Protein--antagonists & inhibitors<br/>Enzyme Inhibitors--administration & dosage<br/>Female<br/>France<br/>Humans<br/>Lymphoma, B-Cell--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Morpholines<br/>Pyridones--administration & dosage<br/>Time Factors<br/>Treatment Outcome